Abstract | PURPOSE: MATERIALS AND METHODS: The CAMUS trial was a randomized, placebo controlled, double-blind, multicenter, North American trial conducted between June 5, 2008 and October 10, 2012, in which 369 men older than 45 years with an AUA symptom score of 8 to 24 were randomly assigned to placebo or dose escalation of saw palmetto, which consisted of 320 mg for the first 24 weeks, 640 mg for the next 24 weeks and 960 mg for the last 24 weeks of this 72-week trial. Serum prostate specific antigen levels were obtained at baseline and at weeks 24, 48 and 72, and were compared between treatment groups using the pooled t test and Fisher's exact test. RESULTS: CONCLUSIONS:
|
Authors | Gerald L Andriole, Christie McCullum-Hill, Gurdarshan S Sandhu, E David Crawford, Michael J Barry, Alan Cantor, CAMUS Study Group |
Journal | The Journal of urology
(J Urol)
Vol. 189
Issue 2
Pg. 486-92
(Feb 2013)
ISSN: 1527-3792 [Electronic] United States |
PMID | 23253958
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
|
Copyright | Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Androgen Antagonists
- Plant Extracts
- Prostate-Specific Antigen
- saw palmetto extract
|
Topics |
- Androgen Antagonists
(administration & dosage, therapeutic use)
- Dose-Response Relationship, Drug
- Double-Blind Method
- Humans
- Male
- Middle Aged
- Plant Extracts
(administration & dosage, therapeutic use)
- Prostate-Specific Antigen
(blood)
- Prostatic Hyperplasia
(blood, drug therapy)
- Serenoa
|